40,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
20 °P sammeln
  • Broschiertes Buch

Beta-thalassemia, an inherited genetic disorder affecting hemoglobin production, has long been managed by conventional treatments such as regular blood transfusions and iron chelation. In this new era, innovative approaches are emerging to transform the management of beta-thalassemia. Gene therapy, which targets the genetic abnormalities that cause the disease, promises more sustainable and potentially curative solutions.This book explores the journey of beta-thalassemia, from conventional treatment to promising innovations. It examines current challenges, recent advances and future prospects,…mehr

Produktbeschreibung
Beta-thalassemia, an inherited genetic disorder affecting hemoglobin production, has long been managed by conventional treatments such as regular blood transfusions and iron chelation. In this new era, innovative approaches are emerging to transform the management of beta-thalassemia. Gene therapy, which targets the genetic abnormalities that cause the disease, promises more sustainable and potentially curative solutions.This book explores the journey of beta-thalassemia, from conventional treatment to promising innovations. It examines current challenges, recent advances and future prospects, offering a comprehensive overview for healthcare professionals, patients and their families. By highlighting the progress made and the hopes raised by new technologies, it underlines the importance of continuous innovation to improve the lives of people with this complex disease.
Autorenporträt
Ghachem Ikbel y Kaabar Yassine son dos hematólogos especializados en biología con más de 8 años de experiencia que ejercen en el Hospital TAher Maamouri de Nabeul (Túnez). Miembros de la SFH y la EHA. Innovadores en diagnóstico avanzado y atención personalizada.